Résultats de recherche
Martin Shkreli est un ancien gestionnaire de fonds d'investissement américain, spécialisé dans les entreprises de soins de santé. Il est le cofondateur de MSMB Capital Management, de Retrophin Inc et le fondateur de Turing Pharmaceuticals AG, ainsi que le cofondateur de Retrophin LLC, une société de biotechnologie fondée en 2011.
Martin Shkreli (/ ˈ ʃ k r ɛ l i /; born March 17, 1983) is an American investor and businessman. He was convicted of financial crimes for which he was sentenced to seven years in federal prison, being released on parole after roughly six and a half years in 2022, and was fined over 70 million dollars. Shkreli is the co-founder of ...
7 oct. 2024 · La Cour suprême a rejeté lundi l'appel de Martin Shkreli, autrefois surnommé «Pharma Bro» après avoir augmenté le prix d'un médicament qui sauve des vies. Shkreli a fait appel d'une ordonnance de restitution de 64,6 millions $ US de profits que lui et son ancienne société ont engrangés après avoir monopolisé le marché du médicament et augmenté considérablement […]
7 oct. 2024 · WASHINGTON (AP) — The Supreme Court on Monday rejected an appeal from Martin Shkreli, who was once dubbed “Pharma Bro” after jacking up the price of a lifesaving drug. Shkreli appealed an order to return $64.6 million in profits he and his former company reaped after monopolizing the market for the medication and drastically increasing ...
14 janv. 2022 · L’entrepreneur provocateur en pharmacie Martin Shkreli, 38 ans, a été jugé coupable de monopole et condamné, vendredi 14 janvier, à reverser les profits qu’il avait retirés de ses pratiques...
- Le Monde Avec AFP
7 oct. 2024 · The U.S. Supreme Court declined on Monday to hear former pharmaceutical company CEO Martin Shkreli's challenge to a $64.6 million financial penalty imposed by a judge after he raised a lifesaving...
23 janv. 2024 · The FTC and state enforcers won a case against Shkreli and his companies for orchestrating an illegal anticompetitive scheme to protect a monopoly for Daraprim, a life-saving drug. The Second Circuit affirmed the district court ruling and ordered Shkreli to pay $64.6 million in disgorgement.
